HK Stock Market Move | TYK MEDICINES-B(02410) rose more than 13% in early trading. Axitinib hydrochloride tablets have been included in the list of priority review varieties.

TYK MEDICINES-B (02410) soared more than 13% in early trading, rising 8.94% to HK$13.52 at the time of writing, with a turnover of HK$40.7033 million. On the news front, Tongyuan Kang Medicine announced that its new drug, Adotinib Hydrochloride Tablets (TY-9591 Tablets), has been included in the priority review list by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE). It is reported that this drug is intended to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 19 deletion or exon 21 substitution mutations in the epidermal growth factor receptor (EGFR) and central nervous system metastasis. Being included in the priority review indicates that the evaluation process of Adotinib Hydrochloride Tablets will be accelerated, potentially leading to an earlier market launch and providing new treatment options for Chinese patients.